close 74% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 74% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Strona główna・Stock List・FibroGen Inc
Search

FibroGen Inc

Open

SectorHealthcare

11.32 -1.05

Buy

Price update 3 paź 2025, 13:40 UTC

BuySell

Overview

Share price change

24h

Current

Min

11.23

Max

11.68

Key metrics

By Trading Economics

Income

-12M

-7.6M

Sales

-1.4M

1.3M

EPS

-1.88

Profit margin

-564.021

Employees

225

EBITDA

2.6M

-12M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+257.74% upside

Dividends

By Dow Jones

Next Earnings

11 lis 2025

Market Stats

By TradingEconomics

Market Cap

16M

50M

Previous open

12.37

Previous close

11.32

News Sentiment

By Acuity

76%

24%

343 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

0.306 / 0.33939 Support & Resistance

FibroGen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

DJ

Read

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

DJ

Read

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

DJ

Read

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

DJ

Read

20 lut 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

DJ

Read

20 lut 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

DJ

Read

Peer Comparison

Price change

FibroGen Inc Forecast

Price Target

By TipRanks

257.74% upside

12 Months Forecast

Average 43 USD  257.74%

High 43 USD

Low 43 USD

Based on 2 Wall Street analysts offering 12 month price targets forFibroGen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Based on 2 analysts giving stock ratings to FibroGen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.306 / 0.33939Support & Resistance

Short Term

Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Weak Bearish Evidence

Bearish events outweigh bullish events.

Long Term

Weak Bearish Evidence

There is one bearish event.

Sentiment

By Acuity

343 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

MDT

Medtronic PLC

97.25

↑ +1.88%

VEEV

Veeva Systems Inc

300.62

↑ +4.11%

A

Agilent Technologies Inc

139.72

↓-0.04%

HQY

HealthEquity Inc

90.34

↓-0.32%

PHR.US

Phreesia Inc

23.41

↑ +5.4%
help-icon Live chat